Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab. A Randomized Phase II Trial.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 24 Jun 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jun 2017 Results assessing the potential survival benefit of an immediate postoperative intraperitoneal immunotherapy using catumaxomab in patients with gastric peritoneal carcinomatosis, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
10 Feb 2016 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
05 Feb 2016 Planned primary completion date changed from 1 Nov 2014 to 1 Nov 2019, according to ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com